RBC Capital Reiterates Sector Perform on BioCryst Pharma, Maintains $10 Price Target
RBC Capital analyst Brian Abrahams reiterates BioCryst Pharma (NASDAQ:BCRX) with a Sector Perform and maintains $10 price target.
Canadian Agency For Drugs And Technologies In Health Recommends Reimbursement For BioCryst’s ORLADEYO For The Routine Prevention Of Attacks In Hereditary Angioedema Patients In Canada
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) has issued a positive recommendation for
Analyst Sees Attractive Entry Opportunity After BioCryst’s Pipeline Setback
Tucked in its Q4 earnings press release, BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) reported a setback on the early-stage BCX10013 study. The company…
Needham Upgrades BioCryst Pharmaceuticals to Buy, Maintains $14 Price Target
Needham analyst Serge Belanger upgrades BioCryst Pharmaceuticals (NASDAQ:BCRX) from Hold to Buy and maintains $14 price target.
Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023.
Why BioCryst Pharmaceuticals Stock Is Sliding Today
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares are trading lower Tuesday after the company reported worse-than-expected earnings results<
Earnings Scheduled For February 21, 2023
Companies Reporting Before The Bell
• Sohu.com (NASDAQ:SOHU) is likely to report earnings for its fourth quarter.
BioCryst Selects Swixx BioPharma As Commercial Partner For ORLADEYO In Central And Eastern Europe
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into a collaboration with Swixx BioPharma AG to commercialize ORLADEYO® (berotralstat) in Central and Eastern Europe
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Gainers
CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash.
Expert Ratings for BioCryst Pharmaceuticals
Analysts have provided the following ratings for BioCryst Pharmaceuticals (NASDAQ:BCRX) within the last quarter: